Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

LGND

Ligand Pharmaceuticals, Inc

Jan 16 • 04:00PM ET

192.97

-3.11 -1.59 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR VTI IWM VB VBR VXF SPSM IJT IWN SCHA

Scroll to Statements

Index	RUT	P/E	92.88	EPS (ttm)	2.08	Insider Own	2.41%	Shs Outstand	19.66M	Perf Week	-6.62%
Market Cap	3.80B	Forward P/E	22.93	EPS next Y	8.42	Insider Trans	-5.07%	Shs Float	19.21M	Perf Month	0.18%
Enterprise Value	3.58B	PEG	1.23	EPS next Q	1.50	Inst Own	103.62%	Short Float	6.49%	Perf Quarter	6.75%
Income	48.58M	P/S	15.12	EPS this Y	32.06%	Inst Trans	4.40%	Short Ratio	5.67	Perf Half Y	38.73%
Sales	251.23M	P/B	3.99	EPS next Y	11.03%	ROA	4.00%	Short Interest	1.25M	Perf YTD	2.06%
Book/sh	48.34	P/C	5.72	EPS next 5Y	18.69%	ROE	5.42%	52W High	212.49 -9.19%	Perf Year	74.98%
Cash/sh	33.76	P/FCF	123.95	EPS past 3/5Y	- -	ROIC	3.47%	52W Low	93.58 106.21%	Perf 3Y	180.24%
Dividend Est.	-	EV/EBITDA	55.07	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	81.19%	Volatility	6.04% 3.88%	Perf 5Y	173.13%
Dividend TTM	-	EV/Sales	14.27	EPS Y/Y TTM	-9.12%	Oper. Margin	11.48%	ATR (14)	8.48	Perf 10Y	205.40%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	24.30	Sales Y/Y TTM	64.83%	Profit Margin	19.34%	RSI (14)	47.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.69	EPS Q/Q	1559.91%	SMA20	-1.73%	Beta	1.18	Target Price	243.44
Payout	-	Debt/Eq	0.47	Sales Q/Q	122.85%	SMA50	-2.07%	Rel Volume	0.99	Prev Close	196.08
Employees	68	LT Debt/Eq	0.47	Earnings	Nov 06 BMO	SMA200	26.54%	Avg Volume	219.77K	Price	192.97
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.24% 96.55%	Trades		Volume	217,489	Change	-1.59%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260

Show Previous Ratings

Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
01:34PM	Loading…
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
04:00PM	Loading…
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
07:17AM	Loading…
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGND

Ligand Pharmaceuticals, Inc

Upgrade your FINVIZ experience